Therapeutic considerations regarding amyloidosis;Traitements des amyloses en dehors du traitement symptomatique

Revue de Medecine Interne

Volumn 21, Issue 3, 2000, Pages 247-255

  Lebrazi, H ^a   Hachulla, E ^b   Saile R ^a  

^a FACULTÉ DES SCIENCES BEN M SIK   (Morocco)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Amyloidosis; Therapy

Indexed keywords

AMYLOID; ANTHRACYCLINE; AZATHIOPRINE; BETA 2 MICROGLOBULIN; CARMUSTINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DIMETHYL SULFOXIDE; MELPHALAN; METHOTREXATE; PREDNISONE; SERUM AMYLOID P; VINCRISTINE;

AMYLOID NEUROPATHY; AMYLOIDOSIS; FAMILIAL MEDITERRANEAN FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PROTEIN TARGETING; REVIEW; SCINTIGRAPHY; TREATMENT PLANNING;

EID: 0034159836     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(00)80044-2     Document Type: Article

References (105)

1. Lebrazi H, Hachulla E, Saïle R. Mécanismes de l'amylose et protéines impliquées. Rev Méd Interne 2000; 21 : 35-49.
2. Tennent GA, Lovât LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995; 92 : 4299-303.
3. Tan SY, Pepys MB. Amyloidosis. Histopathology 1994; 25 : 403-414.
4. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med 1997; 337 : 898-909.
5. Tan SY, Pepys MB, Hawkins PN. Treatment of amyloidosis. Am J Kidney Dis 1995; 26 : 267-85.
6. Levin M, Franklin EC, Frangione B, Pras M. The amino acid sequence of a major non immunoglobulin component of some amyloid fibrils. J Clin Invest 1972; 51 : 2773-6.
7. Saïle R, Fruchart JC. L'apolipoprotéine sérique amyloïde A (aposaa) : Implication dans l'inflammation et dans les modifications des lipoprotéines. Ann Biol Clin 1990; 48 : 77-85.
8. Dinarello CA. Wolff SM, Goldtinger SF, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever: A doubleblind trial. N Engl J Med 1974; 291 : 934-7.
9. Pras M, Gafni J, Jacob ET, Cabili S, Zemer D, Sohar E. Progrés récents dans la fièvre méditerranéenne familiale. In : Crosnier J, Fuck-Brentano JL, Bach JF, Grünfeld JP, eds. Actualités Néphrologiques de L'Hôpital Necker. Paris : Flammarion Médecine-Sciences; 1983. p. 175-83.
10. Zemer D, Pras M, Sohar E, MOdan M, Cabili S, Gatni J. Colchicine in the prevention and treatment of the amyloidosis of familial mediterranean fever. N Engl J Med 1986: 314 : 1001-5.
11. Ravid M. Robson M, Kedar I. Prolonged colchicine treatment in four patients with amyloidosis. Ann Intern Med 1977; 87 : 568-70.
12. Ravid M, Shapira J, Kedar I, Feigel D. Regression of amyloidosis secondary to granulomatous ileitis following surgical resection and colchicine administration. Acta Hepatogastroenterol (Stuttg) 1979; 26 : 513-5.
13. Escalante A. Ehresmann GR, Quismorio FJ. Regression of reactive systemic amyloidosis due to ankylosing spondylitis following the administation of colchicine. Arthritis Rheum 1991; 34 : 920-2.
14. Greenstein AJ, Sachar DB, Panday AK, Dikman SH, Meyers S, Heimann T, Amyloidosis and inflammatory bowel disease. A 50-year Experience with 25 Patients. Medicine (Baltimore) 1992; 71 : 261-70.
15. Fak AS, Ozener C, Akoglu E. Colchicine and secondary amyloidosis. Ann Intern Med 1992; 117 : 795-6.
16. Kedar I, Ravid M, Sohar E. Gafni J. Colchicine inhibition of caseininduced amyloidosis in mice. Isr J Med Sci 1974; 10 : 787-9.
17. Shirahama T, Cohen AS. Blockage of amyloid induction by colchicine in an animal model. J Exp Med 1974; 140 : 1102-7.
18. Brandwein SR. Sipe JD, Skinner M, Cohen AS. Effect of colchicine on experimental amyloidosis in two CBA/J mouse models. Chronic inflammatory situation and administration of amyloid-enhancing factor during acute inflammation. Lab Invest 1985; 52 : 319-25.
19. Malawista SE. Colchicine, a common mechanism of its anti-inflammatory and antimitotic effects. Arthritis Rheum 1968; 11 : 191-7.
20. Dinarello CA, Chusid MJ, Fauci AS, Gallin JI, Dale DC, Wolff SM. Effect of prophylactic colchicine therapy on leukocyte function in patients with familial mediterranean fever. Arthritis Rheum 1976; 19 : 618-22.
21. Kisilevsky R, Boudreau L, Foster D. Kinetics of amyloid deposition. II. The effect of dimethylsulfoxide and colchicine therapy. Lab Invest 1983; 48 : 60-7.
22. Kedar I, Greenwald M, Ravid M. Treatment of experimental murine amyloidosis with dimethylsulfoxide. Eur J Clin Invest 1977; 7 : 149-50.
23. Ravid M, Kedar I, Sohar E. Effect of a single dose of dimethylsulfoxide on renal amyloidosis. Lancet 1977; i : 730-1.
24. Mignon F, Méry JP, Cuvelier R, Delons S, Meyrier A, Rottenbourg J. L'insuffisance rénale de la maladie périodique peut-être bénéficiée de méthodes thérapeutiques modernes ? Ann Méd Interne 1981 ; 132 : 501-6.
25. Schnitzer TJ, Ansell BM. Amyloidosis in juvenile chronic polyarthritis. Arthritis Rheum 1977; 20 : 245-52.
26. Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987; 6 : 27-38.
27. Falck HM, Skrifvars B, Wegelius O. Treatment of amyloidosis secondary to rheumatoid arthritis with cyclophosphamide. In: Glenner GG, Costa PP, de Freitas F, eds. Amyloid and Amyloidosis 1997, Amsterdam: Excerpta Medica; 1980. p. 592-4.
28. David J, Vouyiouka O. Ansell BM, Hull A. Woo P. Amyloidosis in juvenile chronic arthritis: A morbidity and mortality study. Clin Exp Rheumatol 1993: 11 : 85-90.
29. Berglund K. Thyseil H, Keller C. Results, principles and pitfalls in the management of renal AA amyloidosis: A 10-21 year follwup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993: 20 : 2051-7.
30. Komatsuda A. Morita K, Ohtani H. Yamaguchi A, Miura AB. Remission of the nephrotic syndrome in a patient with renal amyloidosis due to rheumatoid arthritis treated with prednisolone and methotrcxate. Am J Kidney Dis 1998; 32 : E7.
31. Glenner GG. Amyloid deposits and amyloidosis-the β-fibrilloses II. N Engl J Med 1980; 302 : 1333-43.
32. Hardt F. Accelaration of casein induced amyloidosis in mice by immunosuppressive agents. Acta Pathol Microbiol Scand (A) 1971: 79 : 61-4.
33. Glenner GG. Amyloid deposits and amyloidosis the β-fibrilloses I. N Engl J Med 1980; 302 : 1283-92.
34. Glenner GG, Terry W. Harada M, Isersky C. Page D. Amyloid fibril proteins: Proof of homology with immunoglobulin light chains by sequence analyses. Science 1971; 172 : 1150-1.
35. Kyle RA. Bayrd ED. Amyloidosis: Review of 236 cases. Medicine 1975: 54: 271-99.
36. Stone MJ, Frenkel EP. The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurence of amyloidosis. Am J Med 1975; 58 : 601-19.
37. Kyle RA. Greipp PR. Primary systemic amyloidosis. Comparison of melphalan and prednisone versus placebo. Blood 1978: 52: 818-27.
38. Cohen AS, Rubinow A, Anderson JJ. Skinner M, Mason JH. Libbey C, Survival of patients with primary (AD) amyloidosis. Colchicine-treated cases from 1976 to 1983 compared with cases seen in previous years (1961 to 1973). Am J Med 1987: 82 : 1182-90.
39. Kyle RA. Greipp PR. Garton JP. Gertz MA. Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine. Am J Med 1985: 79 : 708-16.
40. Kyle RA, Gertz MA. Greipp PR. Witzig TE, Lust JA. Lacy MQ. et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone. And melphalan. Prednisone. And colchicine. N Engl J Med 1997; 336 : 1202-7.
41. Skinner M, Anderson J. Simms R. Falk R. Wang M. Libbey C et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan. Prednisone. And colchicine versus colchicine only. Am J Med 1996; 100 : 290-8.
42. Dubrey SW. Mendes E. Skinner M. Falk R. Resolution of heart failure in patients with AE amyloidosis. Ann Intern Med 1996: 125 : 481-4.
43. Gertz. MA, Kyle RA. Greipp PR. Response rates and survival in primary systemic amyloidosis. Blood 1991: 77 : 257-62.
44. Jones NF. Hilton PI, Tighe JR. Hobbs JR. Treatment of "primary" renal amyloidosis with melphalan. Lancet 1972: ii : 616-9.
45. Lowenstein J. Gallo G. Remission of the nephrotic syndrome in renal amyloidosis. N Engl J Med 1970 : 282 : 128-38.
46. Méry JP. Mostefa S. Remission in renal amyloidosis. Ann Intern Med 1975; 83 : 581.
47. Triger DR. Joekes AM. Renal amyloidosis. A fourteen-year follow-up. Q J Med 1973: 42 : 15-40.
48. Dikman SH. Kahn T. Grihetz D. Churg J. Resolution of renal amyloidosis. Am J Med 1977; 63 : 430-3.
49. Moreau P. Leblond V. Bourquelot P. Facon T, Huynh A, Caillot D. et ai. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transpaltation in systemic AE amyloidosis: A report in 21 patients. Br J Hacmatol 1998: 101 : 766-9.
50. Commenzo RL. Vosburgh E. Ealk RH, Sanchorawala V. Reisinger J. Dubrey S. et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AE (amyloid light-chain) amyloidosis: Survival and response in 25 patients. Blood 1998; 91 : 3662-70.
51. Commenzo RL. Voshurgh E, Simms RW. Bergethon P, Sarnacki D. Finn K. et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996: 88 : 2801-6.
52. Fermand JP. Levy Y. Gerota J. Benbunan M. Cosset JM. Castaigne S. et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989: 73 : 20-3.
53. Harousseau JL. Attal M, Divine M. Marit G. Leblond V. Stoppa AM. et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma. Blood 1995: 85 : 3077-85.
54. Attal M. Harousseau JL. Stoppa AM. Sotto J.I. Fuzibet JG, Rossi JF. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996: 335 : 91-7.
55. Kyle RA. Pierre RV, Bayrd ED. Primary amyloidosis and acute leukemia associated with melphalan therapy. Blood 1974: 44 : 333-7.
56. Gianni L. Bellotti V. Gianni AM. Merlini G. New drog therapy of amyloidosis: Resorption of al-type deposits with 4'-iodo-4'-deoxydoxorubicin. Blood 1995: 86 : 855-61.
57. Merlini G. Ascari E. Amboldi N. Bellotti V. Arbustini E. Perfetti V, et al. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis. Proc Natl Acad Sci USA 1995: 92 : 2959-63.
58. Levy Y. Belghiti-Deprez D. Sobel A. Treatment of AL amyloidosis without myeloma. Ann Méd Interne 1988: 139 : 190-3.
59. Gertz MA. Lacy MQ. Lust JA. Greipp PR. Witzig TE. Kyle RA. Prospective randomised study of melphalan-prednisone (MP) versus vincristine. BCNU. Melphalan. Cydophosphamide and prednisone (VBMCP) in the treatment of primary systemic amyloidosis (AL). In: Kyle RA. Gentz MA. eds. Amyloid and Amyloidosis 1998. New York: Parthenon Press: 1999. p. 96.
60. Hosenpud JD, Demarco T. Frazier OH, Griffith BP. Uretsky BF. Menkis AH, et al. Progression of amyloid disease and reduced longterm survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. CirculaTion 1991; 84 : 338-43.
61. Hawkins PN. Hall M. Hall R. Penny L. Henderson A. Yacoub M. et al. Regression of AL amyloidosis and prolonged survival following cardiac transplantation and chimiotherapy. In: Kisilevsky R. Benson MD. Frangione B. Gauldie J. Muckle TJ. Young ID. eds. Amyloid and Amyloidosis 1993. New York: Pearl River. Pathernon; 1994. p. 657-9.
62. Dubrey S. Simms RW. Skinner M. Falk RH. Recurrence of primary (AL) amyloidosis in a heart with four-year survival. Am J Cardiol 1995; 76 : 739-41.
63. Benson MD. Wallace MR. Amyloidosis. In: Seriver CR. Beaudet AL. Sly WS. Valle D. eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill: 1989. p. 2439.
64. Pras M. Prelli F. Franklin EL. Frangione B. Primary structure of an amyloid prealbumin variant in familial polyneuropathy of jewish origin. Proc Natl Acad Sci 1983; 8 : 539-42.
65. Tawara S. Nakazato M. Kangawa K. Matsuo H. Araki S. Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 1983; 116 : 880-8.
66. Dwulet FE. Benson MD. Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of swedish origin. Proc Natl Acad Sci USA 1984; 81 : 694-8.
67. Saraiva MJM. Birken S. Costa PP. Goodman DS. Amyloid fibril protein in familial amyloid polyneuropathy, portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984: 74 : 104-19.
68. Wallace MR. Dwulet FE. Comically PM. Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis, J Clin Invest 1986: 78 : 6-12.
69. Dwulet FE. Benson MD. Characterization of transthyretin (prealbumin) variant associated with familial amyloid polyneuropathy type II (indiana/swiss). J Clin Invest 1986; 78 : 880-6.
70. Yoshioka K, Sasaki H, Yoshioka N, Furuya H, Harada T. Kito S, et al. Structure of the mutant prealbumin gene responsible for familial amyloidotic polyneuropathy. Mol Biol Med 1986; 3 : 319-28.
71. Holmgren G, Haettner E, Lindströn A, Lundgren E, Nordenson I, Sandgren O, et al. Homozygosity for the TTR-Met30-gene in a 56 year-old swedish man. Clin Genet 1988; 34 : 333-8.
72. Holmgren G, Steen L, Ekstedt J, Groth CG, Ericzon BG, Eriksson S, et al. Biochemical effect of liver transplantation in two swedish patients with familial amyloidotic polyneuropathy (fap-met30). Clin Genet 1991; 40 : 242-6.
73. Lewis WD, Skinner M, Simms RW, Jones LA, Cohen AS, Jenkins RI. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplant 1994; 8 : 107-10.
74. Holmgren G, Ericzon GB, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341 : 1113-6.
75. Skinner M, Lewis WD, Jones LA, Kasirsky J, Kane K, Ju ST, et al. Liver transplantation as a treatment for familial amyloidotic polyneuropathy. Ann Intern Med 1994; 120 : 133-4.
76. Steen L, Holmgren G, Suhr O, Wikström L, Groth CG, Ericzon GB. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1994; 1 : 138-42.
77. Garcia-Herola A, Prieto M, Pascual S, Berenguer M, Lopez-Viedma B, Mir J. et al. Progression of cardiomyopathy and neuropathy after liver transplantation in a patient with familial amyloidotic polyneuropathy caused by thyrosine-77 transthyretin variant. Liver Transpl Surg 1999; 5 : 246-8.
78. Pomfret EA, Lewis WD, Jenkins RL, Bergethon P, Dubrey SW, Reisinger J, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. TransplantaTion 1998; 65 : 918-25.
79. Koch KM. Dialysis-related amyloidosis. Kidney Int 1992; 41 : 1416-29.
80. Gejyo F. Yamada T, Odani S, Nakagawa Y, Arakawa M, Kunitomo T, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 1985; 129 : 701-6.
81. Ogawa H, Saito A, Hirabayashi N, Hara K. Amyloid deposition in systemic organs in long-term hemodialysis patients. Clin Nephrol 1987; 28: 199-204.
82. Kessler M, Netter P, Azoulay E, Mayeux D, PEre P, Gaucher A. Dialysis-associated arthropathy: A multicenter survey of 171 patients receiving haemodialysis for over 10 years. Br J Rheumatol 1992; 31 : 157-62.
83. Diraimondo CR, Casey FT, Diraimondo ChV, Stone WJ. Pathologic fractures associated with idiopathic amyloidosis of bone in chronic hemodialysis patients. Nephron 1986; 43 : 22-7.
84. Bindi P, Chanard J. Destructive spondyloarthropathy in dialysis patients: An overview. Nephron 1990; 55 : 104-9.
85. Campistol JM, Casey A, Torras A. Soler M, Munoz-Gomez J, Montoliu J. et al. Visceral involvement of dialysis amyloidosis. Am J Nephrol 1987; 7 : 390-3.
86. Hardouin P, Flipo RM, Lecomte-Houcke M, Foissac-Gegoux P, Delcambre B. Amylose des hémodialysés. Recherche d'une diffusion générale par biopsie rectale. Presse Méd 1987; 16 : 445-6.
87. Noel LH, Zingraff J, Bardin T, Atienza C, Kuntz D, Drucke T. Tissue distribution of dialysis amyloidosis. Clin Nephrol 1987; 27 : 175-8.
88. Varga J, Idelson B, Felson D, Skinner M, Cohen AS. Lack of amyloid in abdominal fat aspirates from patients undergoing long term hemodialysis. Arch Intern Med 1987; 147 : 1455-7.
89. Stein G, Schneider A, Thoss K, Ritz E, Schaefer K, Huiler M, et al. Beta 2-microglobulin serum concentration and associated amyloidosis in dialysis patients. Nephrol Dial Transplant 1991; 6 : 57-61.
90. 131I-serum amyloid P component. Lancet 1991; 338 : 335-9.
91. Karlsson FA. Groth T, Sege K, Wibell L, Peterson PA. Turnover in humans of beta 2-microglobulin: The constant chain of hla-antigens. Eur J Clin Invest 1980; 10 : 293-300.
92. Kleinman KS. Coburn JW. Amyloid syndromes associated with hemodialysis. Kidney Int 1989; 35 : 567-75.
93. Ballardie FW, Kerr DNS, Tennent G, Pepys MB. Hemodialysis versus CAPD: Equal predisposition to amyloidosis? Lancet 1986; i : 795-6.
94. Charmes JP, Leroux-Robert C. L'amylose des hémodialysés chroniques. Presse Méd 1991; 20 : 831-3.
95. Ullian ME, Hammond WS, Alfrey AC, Schultz A, Molitoris BA. β2-microglobulin associated amyloidosis in chronic hemodialysis patients with carpal tunnel syndrome. Medicine 1989; 68 : 107-15.
96. Vincent C, Revillard JP, Gallard M, Traeger J. Serum β2-microglobulin in haemodialysed patients. Nephron 1978; 21 : 260-8.
97. Tan SY, Irish A, Winearls C, Brown E, Gower P, Clutterbuck EJ, et al. Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology. Kidney Int 1996; 50 : 282-9.
98. Benson MD, Skinner M, Cohen AS. Amyloid deposition in a renal transplant in familial mediterranean fever. Ann Intern Med 1977; 87 : 31-4.
99. Livneeh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial mediterranean fever. Nephron 1992; 60 : 418-22.
100. Hawkins PN. Richardson S, Vigushin DM, David J, Kelsey CR.Gray RES. et al. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rhumatoid arthritis. Arthritis Rheum 1993; 36: 842-51.
101. Hawkins PN. Richardson S, Macsweeney JE, King AD, Vigushin DM, Lavender JP, et al. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression. Q J Med 1993; 86 : 365-74.
102. Hawkins PN, Vigushin DM, Richardson S, Seymour A, Pepys MB. Evaluation of 100 cases of systemic amyloidosis by serum amyloid P component (SAP) scintigraphy. In: Kisilevsky R, Benson MD, Frangione B, Gauldie J, Muckle TJ. Young ID, eds. AmyLoid and Amyloidosis 1993. New York: Pearl River, Parthenon; 1994. p. 209-11.
103. Saïle R, Deveaux M, Hachulla E, Descamps J. Duquesnoy B, Marchandise X. Iodine 123-labelled serum amyloid P component scintigraphy in amyloidosis. Eur J Nucl Med 1993; 20 : 130-7.
104. Hachulla E. Maulin L, Deveaux M, Facon T, Blétry O, Vanhille P, et al. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: From diagnosis to prognosis. Am J Med 1996; 101 : 77-87.
105. Li XA, Hatanaka K. Guo L, Kitamura Y, Yamamoto A. Binding of serum amyloid P component to heparin in human serum. Biochim Biophys Acta 1994: 1201 : 143-8.